Vagus nerve stimulation

DGAP-News: Precisis concludes funding round of €20 million for its bioelectric brain stimulation system

Thursday, October 14, 2021 - 12:08pm

Heidelberg, Germany, [14 October 2021] - Precisis AG, based in Heidelberg, announced that it has successfully concluded a funding round of 20 million with Cochlear Limited.

Key Points: 
  • Heidelberg, Germany, [14 October 2021] - Precisis AG, based in Heidelberg, announced that it has successfully concluded a funding round of 20 million with Cochlear Limited.
  • Precisis is a medical technology company that develops minimally invasive brain stimulation methods to relieve epilepsy patients from their symptoms.
  • The additional funding will be used to support ongoing clinical studies and to further advance EASEE(R), an implantable bioelectric brain stimulation system that explores novel approaches to treating epilepsy.
  • Angela Liedler, MD, CEO of Precisis AG, is thrilled: "This funding round is an important step in the advancement of bioelectric brain stimulation.

Feinstein Institutes names bioelectronic medicine lab the Tatyana and Alan Forman Family Laboratory of Biomedical Science

Wednesday, October 13, 2021 - 2:00pm

The bioelectronic medicine lab, run by Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes, has been renamed the Tatyana and Alan Forman Family Laboratory of Biomedical Science.

Key Points: 
  • The bioelectronic medicine lab, run by Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes, has been renamed the Tatyana and Alan Forman Family Laboratory of Biomedical Science.
  • View the full release here: https://www.businesswire.com/news/home/20211013005248/en/
    Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes lab is now called the Tatyana and Alan Forman Family Laboratory of Biomedical Science.
  • (Credit: Feinstein Institutes)
    Science, and particularly the exciting field of bioelectronic medicine, is the future of health care, said Mrs. Forman.
  • The Forman Family Lab at the Feinstein Institutes is committed to producing new knowledge to treat disease and alleviate suffering.

Evren Technologies receives FDA Breakthrough Device Designation for the Phoenix® - Revolutionary Transcutaneous Auricular Vagus Nerve Therapy to Treat PTSD

Monday, July 26, 2021 - 6:54pm

GAINESVILLE, Fla., July 26, 2021 /PRNewswire/ -- Evren Technologies, Inc. announced today that its non-invasive Phoenix earbud device received Breakthrough Device Designation from the U.S. Food and Drug Administration for the treatment of Post-traumatic Stress Disorder (PTSD).

Key Points: 
  • GAINESVILLE, Fla., July 26, 2021 /PRNewswire/ -- Evren Technologies, Inc. announced today that its non-invasive Phoenix earbud device received Breakthrough Device Designation from the U.S. Food and Drug Administration for the treatment of Post-traumatic Stress Disorder (PTSD).
  • 7.5 million Americans seek treatment for PTSD every year and the rates tripled during the COVID shutdown.
  • The Phoenix is an earbud that provides personalized medicine that addresses the underlying autonomic imbalance of PTSD by delivering transcutaneous auricular vagal nerve stimulation (taVNS) in a proprietary closed-loop system.
  • The Phoenix medical device provides personalized medicine in a discreet earbud design that delivers transcutaneous auricular vagal nerve stimulation (taVNS).

electroCore to Announce Second Quarter 2021 Financial Results on Thursday, August 5th

Thursday, July 22, 2021 - 1:00pm

electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology.

Key Points: 
  • electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology.
  • The company's current indications are the preventive treatment of cluster headache and migraine and the acute treatment of migraine and episodic cluster headache.

electroCore to Participate in the Ladenburg Thalmann 2021 Virtual Healthcare Conference

Friday, July 9, 2021 - 1:00pm

ROCKAWAY, NJ, July 09, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Dan Goldberger, CEO will present a company overview and be available for 1x1 meetings at the following upcoming conference:

Key Points: 
  • ROCKAWAY, NJ, July 09, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Dan Goldberger, CEO will present a company overview and be available for 1x1 meetings at the following upcoming conference:
    Following the conference a webcast replay of the presentation will be available on the Investor section of the companys website, www.electrocore.com .
  • electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology.
  • The company's current indications are the preventive treatment of cluster headache and migraine and the acute treatment of migraine and episodic cluster headache.

Outlook on the Electrical Stimulation Devices Global Market to 2027 - Featuring Abbott Laboratories, Boston Scientific & BTL Industries Among Others - ResearchAndMarkets.com

Monday, June 28, 2021 - 12:01pm

The "Electrical Stimulation Devices - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Electrical Stimulation Devices - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • The U.S. Market is Estimated at $1.5 Billion, While China is Forecast to Grow at 4.3% CAGR
    The Electrical Stimulation Devices market in the U.S. is estimated at US$1.5 Billion in the year 2020.
  • In the global Vagus Nerve Stimulation (VNS) Devices segment, USA, Canada, Japan, China and Europe will drive the 3.9% CAGR estimated for this segment.
  • Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$790.7 Million by the year 2027.

Feinstein Institutes Scientists Observe Vagus Nerve Stimulation Effect on Brain Activity

Tuesday, June 22, 2021 - 2:26pm

The vagus nerve is a major therapeutic target for the emerging field of bioelectronic medicine, which uses neurostimulation to treat diseases.

Key Points: 
  • The vagus nerve is a major therapeutic target for the emerging field of bioelectronic medicine, which uses neurostimulation to treat diseases.
  • Electrically stimulating the vagus nerve is approved by the Food and Drug Administration as a non-pharmacological treatment for brain diseases, including epilepsy and depression.
  • While the links between the vagus nerve, body and the brain are well documented, the effects of VNS on brain function are complex and only partially understood.
  • The brain monitors and controls healthy organ function because it receives and processes information in the vagus nerve, said Kevin J. Tracey, MD , president and CEO of the Feinstein Institutes.

Vagus Nerve Stimulation Dose Thresholds Studied by Feinstein Institutes

Friday, May 28, 2021 - 2:14pm
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210528005266/en/
    Stavros, Zanos, MD, PhD, from the Institute of Bioelectronic Medicine at the Feinstein Institutes.
  • Factors affecting VNS dose thresholds have not been studied before and, as a result, VNS treatments cannot be systematically calibrated.
  • Researchers developed acute and long-term vagus nerve implants to stimulate the vagus and measure thresholds in rats.
  • With the study of stimulation thresholds, scientists can maintain a consistent dose of stimulation in preclinical research and ultimately in clinical research of VNS.

electroCore to Present at Investor Conferences in June

Wednesday, May 26, 2021 - 12:30pm

ROCKAWAY, NJ, May 26, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced today that its management team will present a several investor conferences during the month of June.

Key Points: 
  • ROCKAWAY, NJ, May 26, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced today that its management team will present a several investor conferences during the month of June.
  • The conferencing details are as follows:
    JMP Securities Life Sciences Conference:
    Dan Goldberger, electroCores Chief Executive Officer, and Brian Posner, Chief Financial Officer, will provide an overview of the Companys during a live presentation and will host virtual one-on-one meetings throughout the day.
  • electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology.
  • The company's current indications are the preventive treatment of cluster headache and migraine and the acute treatment of migraine and episodic cluster headache.

electroCore Supports Results of Lancet Paper Highlighting the Benefits of Vagus Nerve Stimulation for Stroke Patients

Tuesday, May 18, 2021 - 1:56pm

Effective treatments hold particular interest because stroke is the second highest cause of death and the third leading cause of disability globally, with ischemic stroke as the most common type of stroke.

Key Points: 
  • Effective treatments hold particular interest because stroke is the second highest cause of death and the third leading cause of disability globally, with ischemic stroke as the most common type of stroke.
  • In this clinical trial, patients with moderate-to-severe arm impairment after ischemic stroke participated in rehabilitation for two years after the implantation of VNS.
  • Wermer and Dr. Van Der Meij describe current research regarding the potential for non-invasive vagus nerve stimulation (nVNS) as another option for treating stroke, although no results are published yet.
  • \xc2\xa7 360bbbb-3(b)(1), until the authorization is terminated or revoked.\nMore information can be found at:\nFact sheet for healthcare workers: https://www.fda.gov/media/139968/download\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210518005193/en/\n'